We have recently reported that the PD-1 and CTLA4 signaling pathways are active in both effector and regulatory T cells, causing profound immune dysfunctions in the tumor microenvironment. In line with this notion, the dual blockade of PD-1- and CTLA4-conveyed signals may exert robust therapeutic effects. Here, we discuss the mechanisms possibly underlying such a synergic interaction
Immunotherapy targeting the Programmed Death (PD-1) receptor/ligand (L) "checkpoint" rapidly gains g...
Recent investigation into immunoregulatory roles of both TIGIT and PD-1 T cell receptors reveals tha...
Recent investigation into immunoregulatory roles of both TIGIT and PD-1 T cell receptors reveals tha...
We have recently reported that the PD-1 and CTLA4 signaling pathways are active in both effector and...
Tumor progression is facilitated by regulatory T cells (Treg) and restricted by effector T cells. In...
Tumor progression is facilitated by regulatory T cells (Treg) and restricted by effector T cells. In...
Immunotherapy targeting the Programmed Death (PD-1) receptor/ligand (L) "checkpoint" rapidly gains g...
CTLA-4 is a co-receptor on T-cells that controls peripheral tolerance and the development of autoimm...
The role of immune checkpoints in modulating the magnitude as well as the functional profile of T ce...
The role of immune checkpoints in modulating the magnitude as well as the functional profile of T ce...
Background: Checkpoint inhibitors act on exhausted CD8+ T cells and restore their effector function ...
Abstract Immune checkpoints or coinhibitory receptors, such as cytotoxic T lymphocyte antigen (CTLA)...
AbstractCancers can be recognized by the immune system, and the immune system may regulate and even ...
The past few years have witnessed something of a renaissance in the field of cancer immunotherapy, r...
Background: The clinical benefit of immunotherapeutic approaches against cancer has been well establ...
Immunotherapy targeting the Programmed Death (PD-1) receptor/ligand (L) "checkpoint" rapidly gains g...
Recent investigation into immunoregulatory roles of both TIGIT and PD-1 T cell receptors reveals tha...
Recent investigation into immunoregulatory roles of both TIGIT and PD-1 T cell receptors reveals tha...
We have recently reported that the PD-1 and CTLA4 signaling pathways are active in both effector and...
Tumor progression is facilitated by regulatory T cells (Treg) and restricted by effector T cells. In...
Tumor progression is facilitated by regulatory T cells (Treg) and restricted by effector T cells. In...
Immunotherapy targeting the Programmed Death (PD-1) receptor/ligand (L) "checkpoint" rapidly gains g...
CTLA-4 is a co-receptor on T-cells that controls peripheral tolerance and the development of autoimm...
The role of immune checkpoints in modulating the magnitude as well as the functional profile of T ce...
The role of immune checkpoints in modulating the magnitude as well as the functional profile of T ce...
Background: Checkpoint inhibitors act on exhausted CD8+ T cells and restore their effector function ...
Abstract Immune checkpoints or coinhibitory receptors, such as cytotoxic T lymphocyte antigen (CTLA)...
AbstractCancers can be recognized by the immune system, and the immune system may regulate and even ...
The past few years have witnessed something of a renaissance in the field of cancer immunotherapy, r...
Background: The clinical benefit of immunotherapeutic approaches against cancer has been well establ...
Immunotherapy targeting the Programmed Death (PD-1) receptor/ligand (L) "checkpoint" rapidly gains g...
Recent investigation into immunoregulatory roles of both TIGIT and PD-1 T cell receptors reveals tha...
Recent investigation into immunoregulatory roles of both TIGIT and PD-1 T cell receptors reveals tha...